Seeking Alpha
12 Nov 2026, 06:25 UTC · 1h ago
Impax Small Cap Fund Q3 2026 Portfolio Review
Impact · against what's priced in
The portfolio review provides negligible new information for BROS, as its status as a detractor is consistent with current market skepticism regarding growth acceleration. Victory Capital, Dycom, and QXO are noted for their performance in a specific fund, but this lacks the fundamental detail to shift valuations.
- BROS−0.05
Already priced in
- The price assumes
Sustained revenue growth acceleration to the 38% annually
The company's role as a top detractor for the fund aligns with a market that is already refusing to pay for aggressive growth acceleration.
What BROS's price assumes · Sep 2
Search tags
